Clearance of porcine circovirus and porcine parvovirus from porcine-derived pepsin by low pH inactivation and cation exchange chromatography.
anion exchange (AEX) chromatography
cation exchange (CEX) chromatography
minute virus of mice (MVM)
porcine circovirus (PCV)
porcine circovirus Type 1 (PCV1)
porcine circovirus Type 2 (PCV2)
porcine circovirus Type 3 (PCV3)
viral clearance
virus chromatography
Journal
Biotechnology progress
ISSN: 1520-6033
Titre abrégé: Biotechnol Prog
Pays: United States
ID NLM: 8506292
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
11
12
2018
revised:
22
11
2019
accepted:
29
12
2019
pubmed:
29
1
2020
medline:
5
8
2021
entrez:
29
1
2020
Statut:
ppublish
Résumé
The contamination of oral rotavirus vaccines by porcine circovirus (PCV) raised questions about potential PCV contamination of other biological products when porcine trypsin or pepsin is used in production process. Several methods can be potentially implemented as a safety barrier when animal derived trypsin or pepsin is used. Removal of PCV is difficult by the commonly used viral filters with the pore size cutoff of approximately 20 nm because of the smaller size of PCV particles that are around 17 nm. It was speculated that operating the chromatography step at a pH higher than pepsin's low pI, but lower than pIs, of most viruses would allow the pepsin to flow through the resin and be recovered from the flow through pool whilst the viruses would be retained on the resin. In this study, we investigated low pH inactivation of viruses including PCV Type 1 (PCV1) and PCV1 removal by cation exchange chromatography (CEX) in the presence of pepsin. Both parvovirus and PCV1 could be effectively inactivated by low pH and PCV1 could be removed by POROS 50HS CEX. The POROS 50HS method presented in this article is helpful for designing other CEX methods for the same purpose and not much difference would be expected for similar product intermediates and same process parameters. While the effectiveness needs to be confirmed for specific applications, the results demonstrate that both low pH (pH 1.7) and CEX methods were successful in eliminating PCV1 and thus either can be considered as an effective virus barrier.
Substances chimiques
Rotavirus Vaccines
0
Viral Vaccines
0
Pepsin A
EC 3.4.23.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2968Informations de copyright
© 2020 American Institute of Chemical Engineers.
Références
ICH. Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin, Q5A. Geneva, Switzerland: International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use; 1998.
EMA. 2010a. European Medicines Agency sees no safety concerns with the Rotarix oral vaccine. London, UK: European Medicines Agency. Doc. Ref. EMA/CHMP/201923/2010.
EMA 2010b. European Medicines Agency confirms positive benefit-risk balance of Rotarix. London, UK: European Medicines Agency. Doc. Ref. EMA/CHMP/462029/2010.
Victoria JG, Wang C, Jones MS, et al. Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J Virol. 2010;84(12):6033-6040.
Mc Clenaham SD, Krause PR, Uhlenhaut C. Molecular and infectivity studies of porcine circovirus in vaccines. Vaccine. 2011;29(29-30):4745-4753.
Tischer I, Gelderblom H, Vettermann W, Koch MA. A very small porcine virus with circular single-stranded DNA. Nature. 1982;295:64-66.
Allan GM, Ellis JA. Pocine circoviruses: a review. J Vet Diagn Invest. 2000;12:3-14.
Fenaux M, Halbur PG, Gill M, Toth TE, Meng XJ. Genetic characterization of type 2 porcine circovirus (PCV-2) from pigs with postweaning multisystemic wasting syndrome in different geographic regions of North America and development of a differential PCRrestriction fragment length polymorphism assay to detect and differentiate between infectious with PCV-1 and PCV-2. J Clin Microbiol. 2000;38:2494-2503.
Palinski R, Piñeyro P, Shang P, et al. A novel porcine circovirus distantly related to known circoviruses is associated with porcine dermatitis and nephropathy syndrome and reproductive failure. J Virol. 2017;91(1):e01879-e01816.
Klaumann F, Correa-Fiz F, Franzo G, Sibila M, Núñez JI, Segalés J. Current knowledge on porcine circovirus 3 (PCV-3): a novel virus with a yet unknown impact on the swine industry. Front Vet Sci. 2018;5(315):1-13. https://doi.org/10.3389/fvets.2018.00315.
European Pharmocopoeia Commission. General Text 5.2.3. Cell substrates for the production of vaccines for human use. European Pharmacopoeia. 7th ed. Strasbourg: Council of Europe; 2010.
FDA. Characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications. Rockville, MD: Food and Drug Administration; 2010.
EMA 2011. Concept paper for a guideline on the quality of porcine trypsin used in the manufacture of human biological medicinal products. London, UK: European Medicines Agency. Doc. Ref. EMEA/CHMP/BWP 367751/2011.
Yang B, Wang H, Neske F, et al. Porcine circovirus (PCV) removal by Q sepharose fast flow chromatography. Biotechnol Prog. 2013;26:1464-1471.
Nims C, Plavsic M. Circovirus inactivation: a literature review. BioProcess J. 2012;11(1):4-10.
Sofer G, Dorothy CL, Boose JA. Inactivation methods grouped by virus. BioPharm Int. 2003;2003(1):37-42.
Miesegaes G, Baily M, Willkommen H, Chen Q, Roush D, Blümel J, Brorson K. 2010. Proceedings of the 2009 viral clearance symposium. Dev Biol1 33:77-91.
Brorson K, Krejci S, Lee K, Hamilton E, Stein K, Xu Y. Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins. Biotechnol Bioeng. 2003;82:321-329.
Mattila J, Clark M, Liu SJ, et al. Retrospective evaluation of low-pH viral inactivation and viral filtration data from a multiple company collaboration. PDA J Pharm Sci and Tech. 2016;70:293-299.
ASTM E2888-12. 2019. Standard practice for process for inactivation of rodent retrovirus by pH. ASTM International, West Conshohocken, PA, 2019, www.astm.org, https://doi.org/10.1520/E2888-12R19.
Tayot JL, Tardy M, Gattel P, Cueille G, Liautaud J. Large scale use of Spherosil ion exchangers in plasma fractionation. Dev Biol Stand. 1987;67:15-24.
Fahrner RL, Knudsen HL, Basey CD, et al. Industrial purification of pharmaceutical antibodies: development, operation, and validation of chromatography processes. Biotechnol Genet Eng Rev. 2001;18:301-327.
Curtis S, Lee K, Blank GS, Brorson K, Xu Y. Generic/matrix evaluation of SV40 clearance by anion exchange chromatography in flow-through mode. Biotechnol Bioeng. 2003;84(2):179-186.
Strauss DM, Gorrell J, Plancarte M, Blank GS, Chen Q, Yang B. Anion exchange chromatography provides a robust, predictable process to ensure viral safety of biotechnology products. Biotechnol Bioeng. 2008;102(1):168-175.
Miesegaes G, Lute S, Strauss DM, et al. Monoclonal antibody capture and viral clearance by cation exchange chromatography. Biotechnol Bioeng. 2012;109(8):2048-2058.
Strauss DM, Lute S, Tebaykina Z, et al. Understanding the mechanism of virus removal by Q sepharose fast flow chromatography during the purification of CHO-cell derived biotherapeutics. Biotechnol Bioeng. 2009;104(2):371-380.
Kundi M. One-hit models for virus inactivation studies. Antiviral Res. 1999;41(3):145-152.
Welch J, Bienek C, Gomperts E, Simmonds P. Resistance of porcine circovirus and chicken anemia virus to virus inactivation procedures used for blood products. Transfusion. 2006;46(11):1951-1958.
Cheung AK. Comparative analysis of the transcriptional patterns of pathogenic and nonpathogenic porcine circoviruses. Virology. 2003;310(1):41-49.
Wang K, Huang L, Kong J, Zhang X. Expression of the capsid protein of porcine circovirus type 2 in Lactococcus lactis for oral vaccination. J Virol Methods. 2008;150(1-2):1-6.
Plavsic M, Bolin S. Resistance of porcine circovirus to gamma irradiation. BioPharm Int. 2001;14:32-36.